Clinical Trial Update: Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation. [Phase 2]

View source ↗

Summary

A Phase 2 pharmacogenomic study evaluating docetaxel and cisplatin, followed by docetaxel, cisplatin, and irradiation, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Esophageal Adenocarcinomas, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Status: TERMINATED